Last updated on December 2019

Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab


Brief description of study

This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. The study consists of 2 parts and 2 groups, and Part 2 includes 2 stages. The objective of Part 1 is to evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors alone and in combination with systemically administered pembrolizumab for the non-HCC (Group A) and HCC (Group B) cohorts separately. Part 2 consists of 2-stage design to evaluate the efficacy and safety of talimogene laherparepvec in combination with systemic pembrolizumab. Efficacy and safety will be evaluated in each of the six non-HCC tumor types from Group A separately. Similarly, the efficacy and safety of the combination treatment will be determined for Group B HCC subjects.

Clinical Study Identifier: NCT02509507

Find a site near you

Start Over

Research Site

Los Angeles, CA United States
  Connect »

Research Site

Washington, WA United States
  Connect »

Research Site

Louisville, KY United States
  Connect »

Research Site

Saint Louis, MO United States
  Connect »

Research Site

New Brunswick, NJ United States
  Connect »

Research Site

New York, NY United States
  Connect »

Research Site

Houston, TX United States
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Seongnam-si, Gyeonggi-do, Korea, Republic of
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Barcelona, Spain
  Connect »

Research Site

Geneva 14, Switzerland
  Connect »

Research Site

Lausanne, Switzerland
  Connect »

Research Site

Winterthur, Switzerland
  Connect »

Research Site

Zurich, Switzerland
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Pittsburgh, PA United States
  Connect »

Research Site

Salzburg, Austria
  Connect »

Research Site

Tübingen, Germany
  Connect »